

# NIKI-TAG to preserve kidney health in hospitalized children

## NIKI-TAG (Nephrotoxic Injury in Kids-TAG): screening of pediatric hospitalized patients exposed to nephrotoxic drugs and education for reducing the risk of acute kidney injury

Christian Skalafouris<sup>1</sup>, Cecilia Dallan<sup>2</sup>, Aurélie De Mul<sup>2</sup>, Thomas Rudolf von Rohr<sup>1</sup>, Léa Gerard<sup>1</sup>, Alexandra Wilhelm-Bals<sup>2</sup>, Thomas Perneger<sup>3</sup>, Paloma Parvex<sup>2</sup>,

Caroline Fonzo-Christe<sup>1</sup>
1 - Geneva University Hospitals, Clinical Pharmacy Unit, Pharmacy, Geneva, Switzerland. 2 - Geneva University Hospitals, Pediatric Nephrology Unit. 3 - Geneva University, Division of Clinical Epidemiology, Department of Health and Community Medicine

## **Objectives**

To evaluate the impact of a quality improvement program including electronic screening of high-risk patients and education on reducing the risk of acute kidney injury (AKI)

## Conclusion

- A targeted intervention combining automated detection of high-risk patients and caregiver education can prevent nephrotoxic-induced AKI
- Alert management and clinical interventions are subsequently handled by clinical pharmacists



STUDY DESIGN

Observational period Washout period Interventional period (2 months) (11 months)

Electronic screening1 **Educational** program<sup>2</sup>

**Electronic** screening1 + **Nephrologist** intervention

Phonecall to the prescriber to make recommendations on AKI detection or management

## 1 - Electronic screening of high-risk situations

Rules implemented into PharmaCheck<sup>3</sup> to screen daily pediatric patient files (0 -18yrs) to prevent AKI episodes

- 1) ≥ 3 days of prescription length of IV nephrotoxic drugs (Antibiotics, Antivirals, Antifungals, NSAIDs, Immunosuppressants, ACE/ATinhibitors, Cytotoxics)
- 2) ≥ 2 concomitant IV or PO nephrotoxic drugs prescription

### AKI definition according KDIGO guidelines

	Stage	Serum creatinine	Urine output (mL/kg/h)
	1	1.5-1.9 × increase in baseline creatinine within 7 days or ≥26.5 µmol/L increase within 48 hours	<0.5 mL/kg/h for 6-12h (*or >0.5 and <1.0 mL/kg/h for 24h)
	2	2.0-2.9 × increase in baseline creatinine	<0.5 for ≥12h (*or >0.3 and <0.5 mL/kg/h for 24h)
	3	≥3 × increase in baseline creatinine or creatinine ≥353.6 µmol/L (*221 µmol/L) or initiation of renal replacement therapy or GFR <35 mL/min/1.73 m <sup>2</sup>	<0.3 mL/kg/h for ≥24h or anuria for ≥12h

## 2 - Interactive workshops and educational materials

#### Workshops (30–45 min)

- Led by a nephrologist and a pharmacist
- Targeted to physicians and nurses
- Micro-learning, cases discussion using pocket card

#### Pocket card

- AKI definition (KDIGO guidelines)
- List of nephrotoxic drugs
- High-risk situations and management


## 5-minute micro-learning module

- Created using Vyond®
- 5 main classes of nephrotoxic drugs
- Assessment of AKI severity based on KDIGO


https://vimeo.com/685 947091/d6e7f83136








555 alerts





168 participants watched the participated to workshops

#### Distribution of therapeutic classes implicated in alerts



3 Skalafouris C et al. BMC Med Inform Decis Mak 2022:31:22





nephrologists







